pharmaceutical investing NervGen Pharma Completes $10 Million Initial Public Offering; Shares to Commence Trading on TSX-V on March 15, 2019 – Symbol “NGEN”
U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia
The Crushed Pile in Nevada: How a Forgotten 1989 Gold Heap Is Becoming One of America's Few Near-Term Antimony Solutions
